{"organizations": [], "uuid": "216b8e9b7465bba672b67d2f81331162dff881a2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-beigene-and-mirati-therapeutics-an/brief-beigene-and-mirati-therapeutics-announce-exclusive-license-agreement-for-sitravatinib-in-the-asia-pacific-region-idUSFWN1P30HN", "country": "US", "domain_rank": 408, "title": "BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.13, "site_type": "news", "published": "2018-01-08T19:08:00.000+02:00", "replies_count": 0, "uuid": "216b8e9b7465bba672b67d2f81331162dff881a2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-beigene-and-mirati-therapeutics-an/brief-beigene-and-mirati-therapeutics-announce-exclusive-license-agreement-for-sitravatinib-in-the-asia-pacific-region-idUSFWN1P30HN", "ord_in_thread": 0, "title": "BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region", "locations": [], "entities": {"persons": [{"name": "mirati", "sentiment": "none"}], "locations": [{"name": "asia pacific", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "beigene ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "sitravatinib", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Beigene Ltd:\n* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION\n* BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD.\n* BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE\n* BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS\n* BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATIâ€˜S SITRAVATINIB IN ASIA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T19:08:00.000+02:00", "crawled": "2018-01-09T17:08:48.024+02:00", "highlightTitle": ""}